2020 - FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering
Date2020-04-30 - 2020-05-01
Deadline2020-04-20
VenueSan Francisco, CA, USA - United States
KeywordsFDA stem cell therapies; HCT/P products; Regenerative Medicine
Topics/Call fo Papers
Stem cells harness the power to differentiate into numerous cells upon stimulation. This has led to their wide exploration across all of medicine, including high risk diseases. Of course, significant scientific breakthroughs in the use of stem cells to prevent, diagnose, and treat numerous diseases has caused numerous start-up companies to form. Despite, such promise, the FDA has yet to approve stem cell therapies for a wide range of diseases, except cord blood-derived hematopoietic progenitor cells for certain indications. Attend this seminar to learn and apply the definitive ways to needed for the field to progress.
Other CFPs
- Designing and Sustaining New and Existing Product Stability Testing Program
- A Review of the Conditions of Participation for Utilization Review: Are you Compliant?
- Latin America – Understanding Regulatory Compliance Requirements Across the Life Science Industry (Pharmaceuticals, Biologics, Medical Devices, IVDs)
- Pharmacovigilance System Master File (PSMF) - A Practical Approach to Design and Implementation Globally
- 12th International Conference on Information Management and Engineering (ICIME 2020)
Last modified: 2020-02-13 16:19:46